3 results match your criteria: "Centre expert et de coordination interrégional pour la maladie de Parkinson[Affiliation]"
Ann Pharm Fr
November 2022
Service de pharmacie, AP-HM, hôpital de la Timone, 264, rue Saint-Pierre, 13005 Marseille, France. Electronic address:
Context: Parkinson disease is a neurodegenerative disorder characterized by motor and non-motor symptoms. Symptomatic treatment is based on dopaminergic medications. In case of self-medication practices, there may be drug-drug interactions between over-the-counter medication and dopaminergic medications.
View Article and Find Full Text PDFFundam Clin Pharmacol
June 2021
Assistance Publique Hôpitaux de Marseille, Hôpital de la Timone, Service de Neurologie pathologies du mouvement, Centre expert et de coordination interrégional pour la maladie de Parkinson, Marseille, France.
Levodopa (L-dopa) remains the basis of pharmacological treatment of Parkinson's disease (PD). However, L-dopa therapy is associated with the development of complications and presents major challenges in the long-term treatment. Thus, other medications may be suggested to delay and/or reduce the doses of L-dopa in order to prevent complications.
View Article and Find Full Text PDFParkinsonism Relat Disord
August 2019
Department of Neurology, Christian-Albrechts-University, Kiel, Germany. Electronic address:
Background: Programming algorithms have never been tested for outcome. The EARLYSTIM study showed superior outcomes of deep brain stimulation of the subthalamic nucleus (STN-DBS) over best medical treatment in early Parkinson's disease (PD). Patients were programmed according to common guidelines but customized for each patient.
View Article and Find Full Text PDF